復星医薬に関するコメント

$Hang Seng Index(800000.HK)$ concluded the day at 19,617, down 342 pts or 1.7%. $Hang Seng China Enterprises Index(800100.HK)$ sagged 131 pts or 2% to 6,601. $Hang Seng TECH Index(800700.HK)$ faded 137 pts or 3.5% to 3,824. The turnover aggregated $106.657 billion.
Techs slid as the market continued to be watchful of the Sino-US relations:
$阿里巴巴集団(09988.HK)$ dived 3.2% to $84.1.
$テンセント(00700.HK)$ sank 1.9% to $338.4.
$美団点評(03690.HK)$ , $小米集団(01810.HK)$ , ...

The domestic COVID-19 oral drug Azifodine is planned to be sold online, and $復星医薬(02196.HK)$ shares were opened 12% higher to 29 yuan.
$ファイザー(PFE.US)$ $AIM VACCINE(06660.HK)$

Fosun Pharma’s Q3 net profit increased by 41.62% year-on-year, and a total of 9.7 million doses of the mRNA new crown vaccine Fubitai® were administered
$復星医薬(02196.HK)$ Fosun Pharma (02196.HK) yesterday disclosed the third quarterly report data, Q3 company revenue was 10.095 billion yuan, a year-on-year increase of 25.03%; net profit was 1.082 billion yuan, a year-on-year increase of 41.62%.
The growth of Fosun Pharma’s performance is due to alleviation of the pressure of centralized procurement and price reduction of stock varieties. According to the announcement, as of October 24, Fosun Pharma’s Fubitai (mRNA Covid-19 vaccine) has been vaccinated in Hong Kong, Macau and Taiwan over 9.7 million. Agent.
Article excerpted from the U.S. Stock Intelligence Agency

$復星医薬(02196.HK)$ Musk: The future of medicine is mRNA. Basically you can cure everything with mRNA, it's like a computer program that you can program to do whatever you need to do. You can actually turn into a butterfly.
We added fosun Pharmaceutical today.
Because I want to be a butterfly

$キュアバック(CVAC.US)$ $復星医薬(02196.HK)$ Yesterday, Company C announced that it was suspending contracts with manufacturers because peak demand for vaccines had passed, which may have contributed to the sharp drop in vaccine stocks. Careful thought, and, yes, mostly the dozen vaccine, countries don't have the money waiting to donate hate, so several head vaccine company, some actual combat has been reviewed, some also not practical to review, rich have reserves more vaccine, really late development of vaccines can only drink soup, unless all vaccine failure now, must never again, Otherwise, the enthusiasm and difficulty of rer&d will be greater. The failure of C Company is the best proof.